| Hypertension |
1 |
1 |
| ACE Inhibitor |
0 |
0.99 |
| Heart Failure (HF) |
0 |
0.58 |
| Myocardial Infarction (MI) |
0 |
0.54 |
| Blood |
0 |
0.32 |
| Adverse Effects |
0 |
0.18 |
| Patient Safety |
0 |
0.17 |
| Clinical Guidelines |
0 |
0.14 |
| Heart |
0 |
0.14 |
| Arrhythmia |
0 |
0.13 |
| Otolaryngology |
0 |
0.13 |
| Abdominal Infection |
0 |
0.1 |
| Pancreatitis |
0 |
0.1 |
| Grant |
0 |
0.09 |
| Stress |
0 |
0.09 |
| Acute Myocardial Infarction (MI) |
0 |
0.07 |
| Angiotensin II Receptor Blockade |
0 |
0.07 |
| Calcium Channel Blockers |
0 |
0.07 |
| Cerebrovascular Accident |
0 |
0.07 |
| Acute Pancreatitis |
0 |
0.05 |
| Allergy |
0 |
0.05 |
| Angioedema |
0 |
0.05 |
| Angioneurotic Edema |
0 |
0.05 |
| Calcium |
0 |
0.05 |
| Cough |
0 |
0.05 |
| Diuretics |
0 |
0.05 |
| Fellowship |
0 |
0.05 |
| Gastrointestinal Hemorrhage |
0 |
0.05 |
| Generics |
0 |
0.05 |
| Geriatrics |
0 |
0.05 |
| Health Care Quality, Access, and Evaluation |
0 |
0.05 |
| Infarction |
0 |
0.05 |
| New York |
0 |
0.05 |
| Pennsylvania |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Renin-Angiotensin System |
0 |
0.05 |
| Weight Loss |
0 |
0.05 |
| Osteoarthritis |
0 |
0.04 |
| Social Determinants of Health |
0 |
0.04 |
| Urticaria and Angioedema |
0 |
0.04 |
| Weight Management |
0 |
0.04 |